Baird analyst Brian Skorney reiterated an Outperform rating and $101 price target on Sarepta Therapeutics (NASDAQ: SRPT) following positive European ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrustSeptember 6, 2017 11:54 AM Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William BlairSeptember 6, 2017 11:06 AM UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper JaffraySeptember 6, 2017 10:57 AM Sarepta Therapeutics (SRPT): Needham & Company Highlights 2 Significant Positive Implications from Dolodiresen DataSeptember 6, 2017 8:42 AM Sarepta Therapeutics (SRPT) Phase 1/2 Study of Golodirsen in DMD Hits Statistical Significance on all Primary and Secondary EndpointsSeptember 6, 2017 7:05 AM Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable September 6, 2017 7:00 AM Sarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing BellSeptember 5, 2017 10:00 AM